Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Gilead Sciences, Inc. (GILD) — XLV Health Care · S&P 500 Profile |吉利德科學公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Gilead Sciences, Inc. (GILD) — Business, History & S&P 500 Profile |吉利德科學公司介紹

Gilead Sciences company profile · HIV, oncology & liver disease franchises · history · financial snapshot · S&P 500 rank #58 · 吉利德科學公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$197.40B
Oct 28, 2026 close · StockAnalysis
S&P 500 WEIGHT
0.29%
Rank #58 · Oct 29, 2026 (Slickcharts)
FY2025 TOTAL REVENUE
$29.44B
+2% YoY · product sales $28.92B
FY2025 NET INCOME
$8.51B
Net margin 28.9% · diluted EPS $6.78

SNAPSHOT

TickerGILD (NASDAQ)
CompanyGilead Sciences, Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#58 · 0.29% (Oct 29, 2026)
Sector rank (by market cap)#8 in Health Care (Oct 29, 2026)
HeadquartersFoster City, California
FoundedJune 22, 1987, Foster City, California
CEODaniel O’Day (since March 2019)
Employees≈17,000 (Dec 31, 2025, FY2025 10-K)
Market cap$197.40B (Oct 28, 2026 close)
SEC filingsEDGAR — CIK 0000882095

WHAT IT DOES

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. It reports one operating segment; almost all revenue is product sales, led by antiviral franchises built over three decades — HIV first, viral hepatitis second, and a younger oncology business assembled by acquisition.

HIV is the engine: $20.75B of FY2025 revenue (70.5% of the total), led by Biktarvy at $14.33B — a once-daily single-tablet regimen that is the most prescribed HIV treatment in the United States — with Descovy ($2.76B) carrying the prevention (PrEP) side. Liver disease adds $3.22B (Epclusa and Vemlidy in viral hepatitis, Livdelzi in primary biliary cholangitis). Oncology contributes $3.24B: the antibody–drug conjugate Trodelvy ($1.40B) and Kite Pharma’s CAR T cell therapies Yescarta and Tecartus ($1.84B combined). Veklury (remdesivir) has faded to $0.91B as COVID-19 hospitalizations fall.

The model is chronic, guideline-embedded therapy at very high gross margin (78.8% in FY2025) converted into research funding — $5.80B of R&D and more than 50 clinical-stage programs — plus disciplined buying of external science (Pharmasset in 2011, Kite in 2017, Immunomedics in 2020, CymaBay in 2024). The current growth story is lenacapavir, the first-in-class capsid inhibitor dosed twice a year: Sunlenca in treatment and Yeztugo, approved in June 2025 as the first twice-yearly PrEP option.

BUSINESS SEGMENTS — FY2025 REVENUE BY PRODUCT AREA

SegmentRevenueShareYoY
HIV$20.75B70.5%+6%
Oncology$3.24B11.0%−2%
Liver Disease$3.22B10.9%+6%
Veklury (COVID-19)$0.91B3.1%−49%
Other products$0.80B2.7%−10%
Royalty, contract & other$0.53B1.8%+266%
Total revenues$29.44B100%+2%
Source: Gilead FY2025 Form 10-K (fiscal year ended Dec 31, 2025). Gilead reports one operating segment; the split above is the 10-K revenue disaggregation by product area. Biktarvy alone is $14.33B — 48.7% of total revenue.

HISTORY

YearMilestone
1987Founded in Foster City, California, by physician Michael L. Riordan
1992IPO on NASDAQ
2001Viread (tenofovir) approval starts the HIV franchise build-out
2006Atripla — the first once-daily single-tablet HIV regimen (with Bristol-Myers Squibb)
2011Announces the $11B acquisition of Pharmasset, owner of sofosbuvir
2013Sovaldi launches; the curative hepatitis C era begins
2014Harvoni — first all-oral, interferon-free HCV cure regimen
2016Epclusa — first pan-genotypic HCV regimen
2017Acquires Kite Pharma for $11.9B; Yescarta becomes a first-in-class CAR T cell therapy
2018Biktarvy launches and grows into the world’s leading HIV regimen
2019Daniel O’Day becomes chairman and CEO
2020Veklury (remdesivir) is the first FDA-approved COVID-19 treatment; acquires Immunomedics for $21B (Trodelvy)
2022Sunlenca (lenacapavir) approved — first twice-yearly HIV treatment option
2024Acquires CymaBay Therapeutics, adding Livdelzi (primary biliary cholangitis)
2025Yeztugo (lenacapavir) approved as twice-yearly HIV prevention (PrEP)

COMPETITIVE POSITION

  • The HIV standard of care — Biktarvy is the most prescribed HIV regimen in the US; the challenger is GSK’s ViiV Healthcare, which competes with oral two-drug regimens (Dovato) and long-acting injectables (Cabenuva, Apretude).
  • Lenacapavir moat — a first-in-class capsid inhibitor with twice-yearly dosing in both treatment (Sunlenca) and prevention (Yeztugo); no rival matches that dosing interval.
  • A curing, shrinking HCV pool — Epclusa/Harvoni revenue declines structurally as patients are cured; AbbVie’s Mavyret is the remaining competitor.
  • Oncology is the contested frontier — Trodelvy (Trop-2 ADC) races Daiichi Sankyo / AstraZeneca’s Enhertu and Dato-DXd, while Kite defends the CAR T lead against Bristol-Myers Squibb and allogeneic upstarts amid complex manufacturing.
  • Balance-sheet firepower — $10.61B of cash and marketable debt securities and $10.0B of operating cash flow fund the pipeline and bolt-on deals.

FINANCIAL SNAPSHOT — FY2025

Total revenues$29.44B (+2% YoY)
Product sales$28.92B · 98.2% of total revenue
Gross profit$23.21B · 78.8% margin
Operating income$10.02B · 34.0% margin
Net income$8.51B · 28.9% margin
Diluted EPS$6.78 (vs $0.38 in FY2024 — see note)
Operating cash flow$10.02B
Cash & marketable debt securities$10.61B (Dec 31, 2025)
Research & development$5.80B · 19.7% of revenue
Source: Gilead FY2025 Form 10-K. FY2024 EPS was depressed by a $3.9B acquired IPR&D charge (CymaBay) and a $4.2B impairment (Immunomedics assets); FY2025 net income recovered as those charges did not repeat at the same scale.

KEY RISKS

  • HIV concentration — HIV is 70.5% of revenue and Biktarvy alone 48.7%; any share loss, pricing action or safety signal on one regimen is a company-level event.
  • Policy and pricing pressure — the Medicare Part D redesign already weighed on FY2025 realized prices, and the FY2025 10-K flags US policy developments as an expected FY2026 headwind; federal drug-pricing negotiation looms over mature brands.
  • Veklury fade — down 49% in FY2025 to $0.91B and guided lower as COVID-19 hospitalizations normalize.
  • Cell therapy headwinds — cell therapy sales fell 7% in FY2025 on competition, and management expects a further decline in 2026 before new indications and manufacturing gains can offset it.
  • Charge volatility — acquired IPR&D and impairment charges ($1.02B and $0.59B in FY2025) have swung reported earnings repeatedly; headline EPS needs adjusting before it is comparable.

WHY IT MATTERS FOR THE S&P 500

Gilead is the S&P 500’s #58 constituent at a 0.29% weight and #8 within Health Care — a 1% move in GILD moves the index by only about 0.3 basis points on its own, but the stock is the market’s purest large-cap read on HIV economics and a top-ten health care name, so its results steer biotech sentiment well beyond its weight (XLV and XBI read-through).

For index and 0DTE traders specifically: Gilead reports in the February / May / August / November biotech windows, lenacapavir regulatory and clinical headlines land without warning, and HIV policy news out of Washington can gap the whole antiviral complex — GILD is usually the first name through which that flow expresses itself.

SOURCES & METHODOLOGY

Financials, product sales, employeesGilead Sciences FY2025 Form 10-K (filed Feb 24, 2026; fiscal year ended Dec 31, 2025)
Index weight & rankSlickcharts S&P 500 weights, crawled Oct 29, 2026 (frozen benchmark)
Market cap & sector rankStockAnalysis S&P 500 list, Oct 28, 2026 close snapshot; GICS sector per List of S&P 500 companies (Wikipedia)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

GILEAD

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號GILD(NASDAQ)
公司Gilead Sciences, Inc.(吉利德科學)
GICS 板塊/行業醫療健康(XLV)/生物科技
標普500排名(按權重)#58 · 0.29%(2026年10月29日)
板塊內排名(按市值)醫療健康 #8(2026年10月29日)
總部加州福斯特城
成立1987年6月22日,加州福斯特城
執行長Daniel O’Day(2019年3月起)
員工約17,000人(2025年12月31日,FY2025 10-K)
市值$197.40B(2026年10月28日收盤)
SEC 申報EDGAR — CIK 0000882095

業務概覽

吉利德科學是一家生物製藥公司,專注於未滿足醫療需求領域的創新藥物發現、開發與商業化。公司只有一個經營板塊,收入幾乎全部來自產品銷售,由三十年累積的抗病毒產品線主導——HIV 第一、病毒性肝炎第二,加上以收購組建的較年輕腫瘤業務。

HIV 是引擎:FY2025 收入 $20.75B(佔總收入 70.5%),由 Biktarvy 的 $14.33B 領跑——這款每日一次的單片方案是美國處方量最高的 HIV 治療;Descovy($2.76B)承擔預防(PrEP)一端。肝病貢獻 $3.22B(病毒性肝炎的 Epclusa 與 Vemlidy、原發性膽汁性膽管炎的 Livdelzi)。腫瘤貢獻 $3.24B:抗體藥物偶聯物 Trodelvy($1.40B)與 Kite Pharma 的 CAR T 細胞療法 Yescarta、Tecartus(合併 $1.84B)。Veklury(瑞德西韋)隨新冠住院人數下降已回落至 $0.91B。

商業模式是嵌入臨床指引的慢性療法、極高的毛利率(FY2025 為 78.8%),轉化為研發資金——$5.80B 研發支出與 50 多個臨床階段項目——以及紀律性的外部科學收購(2011 年 Pharmasset、2017 年 Kite、2020 年 Immunomedics、2024 年 CymaBay)。當前增長故事是 lenacapavir:首創的衣殼抑制劑、每半年給藥一次,治療端是 Sunlenca,預防端是 2025 年 6 月獲批、首個每半年一次的 PrEP 方案 Yeztugo。

業務板塊 — FY2025 按產品領域劃分的收入

板塊收入佔比同比
HIV$20.75B70.5%+6%
腫瘤$3.24B11.0%−2%
肝病$3.22B10.9%+6%
Veklury(新冠)$0.91B3.1%−49%
其他產品$0.80B2.7%−10%
授權、合約及其他$0.53B1.8%+266%
總收入$29.44B100%+2%
來源:吉利德 FY2025 Form 10-K(會計年度截至2025年12月31日)。吉利德只有一個經營板塊,上表為 10-K 按產品領域的收入拆分。單是 Biktarvy 就有 $14.33B,佔總收入 48.7%。

歷史沿革

年份里程碑
1987由醫師 Michael L. Riordan 在加州福斯特城創立
1992於 NASDAQ 上市
2001Viread(tenofovir)獲批,HIV 產品線開始成形
2006Atripla——首個每日一次的 HIV 單片方案(與必治妥施貴寶合作)
2011宣布以 $11B 收購擁有 sofosbuvir 的 Pharmasset
2013Sovaldi 上市,可治癒的 C 型肝炎時代開啟
2014Harvoni——首個全口服、無干擾素的 HCV 治癒方案
2016Epclusa——首個泛基因型 HCV 方案
2017以 $11.9B 收購 Kite Pharma;Yescarta 成為首創 CAR T 細胞療法
2018Biktarvy 上市並成長為全球領先的 HIV 方案
2019Daniel O’Day 出任董事長兼執行長
2020Veklury(瑞德西韋)成為首個獲 FDA 批准的新冠治療;以 $21B 收購 Immunomedics(Trodelvy)
2022Sunlenca(lenacapavir)獲批——首個每半年一次的 HIV 治療選項
2024收購 CymaBay Therapeutics,納入 Livdelzi(原發性膽汁性膽管炎)
2025Yeztugo(lenacapavir)獲批為每半年一次的 HIV 預防(PrEP)方案

競爭地位

  • HIV 標準療法——Biktarvy 是美國處方量最高的 HIV 方案;挑戰者是 GSK 旗下 ViiV Healthcare,以口服雙藥方案(Dovato)與長效注射劑(Cabenuva、Apretude)競爭。
  • Lenacapavir 護城河——首創衣殼抑制劑,治療(Sunlenca)與預防(Yeztugo)均可每半年給藥一次,沒有對手能匹配這個給藥間隔。
  • 治癒中縮小的 HCV 池——患者被治癒後 Epclusa/Harvoni 收入結構性下降;AbbVie 的 Mavyret 是僅餘的主要對手。
  • 腫瘤是競爭前線——Trodelvy(Trop-2 ADC)與第一三共/阿斯利康的 Enhertu、Dato-DXd 競速;Kite 以 Yescarta 守住 CAR T 領先,但面對必治妥施貴寶與異體療法新進者及複雜的製造要求。
  • 資產負債表火力——$10.61B 現金與可出售債務證券、$10.0B 經營現金流,支撐研發管線與補強式收購。

財務快照 — FY2025

總收入$29.44B(同比 +2%)
產品銷售$28.92B · 佔總收入 98.2%
毛利$23.21B · 毛利率 78.8%
營業利潤$10.02B · 利潤率 34.0%
淨利潤$8.51B · 淨利率 28.9%
稀釋 EPS$6.78(FY2024 為 $0.38,見註)
經營現金流$10.02B
現金與可出售債務證券$10.61B(2025年12月31日)
研發支出$5.80B · 佔收入 19.7%
來源:吉利德 FY2025 Form 10-K。FY2024 的 EPS 被 $3.9B 收購研發費用(CymaBay)與 $4.2B 減值(Immunomedics 資產)壓低;FY2025 淨利潤隨該等費用未以同等規模重現而回升。

主要風險

  • HIV 集中度——HIV 佔收入 70.5%、Biktarvy 單品佔 48.7%;任何份額流失、定價行動或安全性信號都是公司級事件。
  • 政策與定價壓力——Medicare Part D 改革已在 FY2025 壓低實現價格,FY2025 10-K 亦把美國政策發展列為 FY2026 的預期逆風;聯邦藥價談判懸在成熟品牌之上。
  • Veklury 消退——FY2025 跌 49% 至 $0.91B,管理層指引隨新冠住院正常化進一步下降。
  • 細胞療法逆風——細胞療法銷售 FY2025 因競爭跌 7%,管理層預期 2026 年再降,之後才靠新適應症與製造改善抵消。
  • 費用波動——收購研發與減值費用(FY2025 分別 $1.02B 與 $0.59B)多次大幅擺動 reported 盈利;headline EPS 需先調整才可比。

對標普500的重要性

吉利德是標普500 第 #58 大成分股、權重 0.29%,在醫療健康板塊內排 #8——GILD 波動 1% 只直接推動指數約 0.3 個基點,但它是市場上最純粹的大型 HIV 曝險、又是醫療健康前十名成分,其業績對生物科技情緒的引導遠超自身權重(XLV 與 XBI 都會跟動)。

對指數與 0DTE 交易者:吉利德在 2 月、5 月、8 月、11 月的生物科技財報窗口發報,lenacapavir 的監管與臨床消息會無預警落地,華盛頓的 HIV 政策新聞能讓整個抗病毒族群跳空——GILD 通常是這類資金流最先表達的 tick。

來源與方法

財務、產品銷售、員工吉利德 FY2025 Form 10-K(2026年2月24日申報;會計年度截至2025年12月31日)
指數權重與排名Slickcharts 標普500權重,2026年10月29日抓取(凍結基準)
市值與板塊排名StockAnalysis 標普500清單,2026年10月28日收盤快照;GICS 板塊據 S&P 500 公司清單(Wikipedia)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
圖表SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

GILEAD

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · GILD
Data as of Oct 29, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Amphenol Corporation (APH) — XLK Information Technology · S&P 500 Profile |安費諾公司介紹Next · GE Aerospace (GE) — XLI Industrials · S&P 500 Profile |GE航空航天公司介紹

Entered 2026-10-29 10:44 · updated 2026-11-14 23:27 · rev 6